BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30477242)

  • 1. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
    Yu KH; Ricigliano M; McCarthy B; Chou JF; Capanu M; Cooper B; Bartlett A; Covington C; Lowery MA; O'Reilly EM
    Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30477242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
    Yu KH; Park J; Mittal A; Abou-Alfa GK; El Dika I; Epstein AS; Ilson DH; Kelsen DP; Ku GY; Li J; Park W; Varghese AM; Chou JF; Capanu M; Cooper B; Bartlett A; McCarthy D; Sangar V; McCarthy B; O'Reilly EM
    Cancer; 2022 Aug; 128(15):2958-2966. PubMed ID: 35647938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.
    Yu KH; Ricigliano M; Hidalgo M; Abou-Alfa GK; Lowery MA; Saltz LB; Crotty JF; Gary K; Cooper B; Lapidus R; Sadowska M; O'Reilly EM
    Clin Cancer Res; 2014 Oct; 20(20):5281-9. PubMed ID: 25107917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.
    Veenstra VL; Damhofer H; Waasdorp C; van Rijssen LB; van de Vijver MJ; Dijk F; Wilmink HW; Besselink MG; Busch OR; Chang DK; Bailey PJ; Biankin AV; Kocher HM; Medema JP; Li JS; Jiang R; Pierce DW; van Laarhoven HWM; Bijlsma MF
    Oncogenesis; 2018 Nov; 7(11):87. PubMed ID: 30442938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant nab-paclitaxel plus gemcitabine
    Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
    World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
    Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
    Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
    J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and resource utilization of
    Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
    Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
    Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
    Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity.
    Zhang Y; Hochster H; Stein S; Lacy J
    Exp Hematol Oncol; 2015; 4():29. PubMed ID: 26451276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
    Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
    J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
    Woo W; Carey ET; Choi M
    Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
    Awasthi N; Monahan S; Stefaniak A; Schwarz MA; Schwarz RE
    Oncotarget; 2018 Jan; 9(4):5274-5286. PubMed ID: 29435178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
    Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
    Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
    Frappart PO; Hofmann TG
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.
    Isacoff WH; Cooper B; Bartlett A; McCarthy B; Yu KH
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.